The company is evaluating whether the drug, which targets cardiac complications, might be used treat patients with other ...

SAN DIEGO, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare ...

Evan McMenamin said his brother Travis, "never lets it get him down" despite the "incredible challenges" he faces ...

There is an unmet need for therapies targeting Duchenne muscular dystrophy (DMD)–related heart disease, and phase 2 results ...

Medera, Inc., (“Medera”), a clinical-stage biotechnology company, announced today that the management team will participate ...

Duchenne muscular dystrophy (DMD) treatment ifetroban led to improvements in measures of heart function in a Phase 2 clinical ...

Despite the obstacles, Riley Herrera had a life filled with family, sports, travel, faith and hope before his death on Nov.

High-dose treatment with the therapy was found to cause a 3.3% overall improvement in left ventricular ejection fraction.

Real-time index price for TSX Composite Weight Index (TXCE), along with buy or sell indicators, analysis, charts, historical ...

Cumberland Pharmaceuticals' Phase 2 trial shows ifetroban improves heart function in Duchenne muscular dystrophy patients.

NASHVILLE, Tenn. - Cumberland Pharmaceuticals Inc. (NASDAQ: NASDAQ:CPIX), a specialty pharmaceutical company with a market ...